恶性黑色素瘤手术辅助治疗中延长化疗、免疫治疗及化疗联合免疫治疗的对照研究（试验6）：初步报告 - Suppr | 超能文献

Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.

作者信息

Veronesi U, Beretta G

出版信息

Recent Results Cancer Res. 1978;68:375-9. doi: 10.1007/978-3-642-81332-0_56.

DOI:10.1007/978-3-642-81332-0_56

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.恶性黑色素瘤手术辅助治疗中延长化疗、免疫治疗及化疗联合免疫治疗的对照研究（试验6）：初步报告

Recent Results Cancer Res. 1978;68:375-9. doi: 10.1007/978-3-642-81332-0_56.

2

Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.恶性黑色素瘤的辅助治疗：免疫疗法、化疗及联合治疗的试验

Recent Results Cancer Res. 1978;68:380-6. doi: 10.1007/978-3-642-81332-0_57.

3

Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.接受化疗和特异性主动免疫治疗的播散性恶性黑色素瘤患者的肿瘤消退及生存情况

Eur J Cancer (1965). 1977 Oct;13(10):1169-73. doi: 10.1016/0014-2964(77)90017-2.

4

Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.卡介苗（BCG）或二甲基三氮烯咪唑甲酰胺（DTIC）辅助治疗在控制II期黑色素瘤微小残留病中的价值。

Recent Results Cancer Res. 1978;68:367-74. doi: 10.1007/978-3-642-81332-0_55.

5

Letter: Chemoimmunotherapy of malignant melanoma.信函：恶性黑色素瘤的化学免疫疗法。

N Engl J Med. 1975 Jan 16;292(3):159-60. doi: 10.1056/NEJM197501162920311.

6

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.转移性黑色素瘤联合化疗与特异性主动免疫疗法的临床试验

Br J Cancer. 1976 Aug;34(2):174-9. doi: 10.1038/bjc.1976.140.

7

Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.卡介苗免疫疗法联合达卡巴嗪（NSC-45388）治疗恶性黑色素瘤。

Cancer Treat Rep. 1976 Feb;60(2):177-82.

8

Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.“高危”原发性恶性黑色素瘤辅助治疗的随机试验

Surgery. 1978 Jun;83(6):677-81.

9

Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.黑色素瘤高危患者的辅助化疗和免疫治疗

Surg Gynecol Obstet. 1978 Feb;146(2):230-2.

10

A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.

Cancer. 1985 Feb 15;55(4):707-12. doi: 10.1002/1097-0142(19850215)55:4<707::aid-cncr2820550406>3.0.co;2-5.

引用本文的文献

1

Adjuvant BCG immunotherapy for stage I and II malignant melanoma.I期和II期恶性黑色素瘤的辅助卡介苗免疫疗法。

Can Med Assoc J. 1983 Jun 1;128(11):1291-5.